The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for the following active substances / combinations of active substances in the context of a so-called open house procedure:

Adalimumab (L04AB04)

Dapagliflozin (A10BK01)

Inclisiran (C10AX16)

Peginterferon alfa-2a (L03AB11)

Ranolazin (C01EB18)

Ustekinumab (L04AC05)

Vilanterol & Fluticasonfuroat (R03AK10)

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned.

The earliest contract start is 01.02.2023. Based on this, the contract term is a maximum of 24 months.

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned.

The earliest contract start is 01.02.2023. Based on this, the contract term is a maximum of 24 months.